WOMEN’S HEALTH • MENOPAUSE
What women were never told about hormone therapy
By Corinne Furnari, PA, CDN
For more than 20 years, one message dominated the conversation about menopause hormone therapy: Be afraid.
This message was not limited to women in their 50s, 60s, or 70s. Women of every age heard the simplified claim that estrogen causes cancer. Many clinicians stopped prescribing it. Many women were told to endure hot flashes, sleepless nights, vaginal dryness, painful sex, urinary symptoms, mood changes, and accelerating bone loss because hormone therapy was simply “too dangerous.”
Then the FDA changed its position.
In November 2025, the agency initiated the removal of broad boxed warnings from menopausal hormone therapy products. In February 2026, it approved revised labeling for the first six products. Statements about cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warning. The endometrial cancer boxed warning remains for systemic estrogen used without adequate protection of the uterine lining.
For women who suffered through years of symptoms because they were told there was no safe help, this is more than a technical change in labeling. It is a reason to reopen the treatment conversation.
LISTEN TO THE CONVERSATION
Carol Petersen, RPh, CNP, and I explored what changed and what women can ask of their practitioners in our episode “They Changed Their Mind.” Watch it here →
How One Study Denied Menopause Care for a Generation
The fear surrounding hormone therapy can be traced largely to the Women’s Health Initiative, or WHI. Its combined estrogen-plus-progestin trial was stopped early in 2002. The headlines were immediate and frightening. Hormone therapy became associated with breast cancer, cardiovascular disease, stroke, and blood clots. By 2003, prominent boxed warnings appeared on menopausal hormone products.
But the public message left out important context. The average participant was 63. The trial evaluated whether particular oral regimens could prevent chronic disease. It did not simply ask whether a 50-year-old with severe hot flashes could benefit from an individualized treatment plan.
The WHI studied oral conjugated equine estrogens, derived from horses, with or without medroxyprogesterone acetate, a synthetic progestin. It did not study the now commonly used combination of human-identical estradiol and natural micronized progesterone. The hormone, dose, delivery route, and timing all matter.
“Hormone therapy” is not one treatment. Women should never have been given one sweeping answer.
This changed what happened in examination rooms. Women waking night after night drenched in sweat, struggling with painful sex, urinary symptoms, mood changes, and exhaustion were often sent home to endure symptoms that could have been treated.
Menopause care also lost ground in medical training. In a 2013 survey, only 20.8% of OB/GYN residents reported that their program had a formal menopause medicine curriculum. In a separate 2019 survey, only 6.8% of responding residents felt adequately prepared to care for women experiencing menopause.
The WHI reported real risks with the particular oral regimens it studied. The failure was applying those results to every woman, every age, every formulation, and every route of delivery as though they were identical.
A PERSONAL INVITATION
Were you told to simply live with your symptoms?
We can review your history, symptoms, testing, and treatment options together. Your first visit gives us time to build a plan around you.
Explore a consultation with Corinne →What the Numbers Actually Show
When researchers separated estrogen alone from estrogen combined with a specific synthetic progestin, the breast cancer findings differed. The two WHI trials enrolled different groups of women. Read each result against its own placebo group.
CHART 01 • RANDOMIZED WHI TRIALS
Breast cancer incidence was different in the two regimens
Relative index within each separate trial. Each trial’s placebo group = 100.
Trial A: women with a prior hysterectomy
22% lower breast cancer incidence with estrogen alone
Trial B: women with a uterus
28% higher breast cancer incidence with this combined regimen
These results tell a very different story from the blanket statement that “estrogen causes cancer.” They do not mean estrogen alone is the right regimen for everyone. Women with a uterus generally need a progestogen with systemic estrogen to protect the uterine lining.
Natural micronized progesterone should not be treated as though it were the same molecule as the synthetic medroxyprogesterone acetate used in the WHI. Research suggests breast cancer risk may differ by progestogen. A systematic review found no increased breast cancer risk with estrogen plus micronized progesterone for up to five years; evidence beyond five years is more limited. This distinction deserves a place in an informed conversation.
Beyond hot flashes: what else does the research show?
Brain and heart. A large 2024 Medicare analysis associated estrogen-only use after age 65 with 2% lower dementia risk and 11% lower heart attack risk. Because this was observational research, it cannot prove estrogen caused those differences.
Bones. Randomized trials found that hormone therapy reduces fractures. Bone protection is an established benefit worth discussing alongside symptom relief.
Urinary health. For recurrent urinary tract infections after menopause, the evidence specifically favors vaginal estrogen. Oral estrogen did not show the same benefit in a meta-analysis of randomized trials.
Skin. Small studies report improvements in collagen, thickness, hydration, or elasticity with estrogen. This remains an emerging area of research.
The 2024 Medicare study also challenges the idea that treatment must stop at a certain birthday. Among women using hormone therapy beyond 65, results differed by hormone type, dose, and route. Age alone should not close the conversation; an individual assessment still matters.
CHART 02 • RANDOMIZED TRIAL META-ANALYSIS
Vaginal estrogen and recurrent UTIs
Relative risk compared with placebo. Placebo = 100.
The FDA Warning Changed. The Biology Did Not.
The FDA’s change corrects how risk was presented in the most prominent part of the label. It does not make every formulation or treatment plan interchangeable. A useful menopause plan starts with the woman in front of us.
Local or systemic?
Low-dose vaginal estrogen primarily treats vaginal and urinary tissues. Systemic pills, patches, gels, and sprays circulate throughout the body.
Oral or through the skin?
Route of delivery can affect clotting, triglycerides, gallbladder risk, and how hormones are metabolized.
Estrogen with what?
Micronized progesterone can protect the uterine lining when systemic estrogen is used by a woman with a uterus. I also consider progesterone’s broader role for women who have had a hysterectomy; that choice should be individualized.
At what age?
Age 60 or 65 is not an automatic cutoff. Starting later calls for a careful review of personal risks and benefits, often beginning at a low dose and adjusting slowly.
If you were told that all estrogen causes cancer, that every hormone regimen is the same, or that a birthday alone ends the conversation, you were not given the full story.
Women deserve an evaluation that takes their symptoms, medical history, goals, and the actual treatment options seriously. Removing the broad warning reopens a door that should never have been closed to an entire generation of women.
YOUR NEXT STEP
Let’s talk about your menopause plan.
Bring your questions, your health history, and any recent testing. We’ll look at the whole picture and discuss options that fit your needs.
Schedule a new patient consultation →To be continued.
